Resonetics® Expands Bioelectronics Implant Offering with Acquisition of Manufacturing Assets and Process IP from Med-Ally

Rhea-AI Summary

Resonetics (NYSE:CG) announced on January 6, 2026 the acquisition of manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators (IPG/EPG) and leads from Med-Ally.

The deal combines Resonetics' implantable battery technologies with Med-Ally's pulse-generator manufacturing and assembly capabilities, enabling an integrated offering from energy source to active implantable device for neuromodulation, brain-computer-interface (BCI), and cardiac rhythm management (CRM) markets. The acquired assets will be transferred to an existing Resonetics facility. This is Resonetics' third notable transaction in the past 12 months, following prior asset acquisitions for nitinol gun-drilling and micro-molding.

Positive

• Acquired IPG/EPG manufacturing assets and process IP from Med-Ally on Jan 6, 2026
• Adds integrated offering: batteries plus pulse generators for implantable devices
• Targets three markets: neuromodulation, BCI, CRM
• Assets to be relocated into an existing Resonetics facility, enabling consolidation

Negative

• None.

Key Figures

Share price $64.03 Price before article on 2026-01-06

Price change 5.21% 24h move prior to publication

Trading volume 2,118,034 shares Volume today vs 20-day avg 2,319,393

Market cap $21,934,582,178 Pre-news market capitalization

Transaction count Third notable transaction Resonetics acquisitions in last twelve months

Market Reality Check

$65.41 Last Close

Volume Volume 2,118,034 is slightly below the 20-day average of 2,319,393 (relative volume 0.91). normal

Technical Shares at $64.03 are trading above the 200-day MA of $53.94 and sit 8.33% below the 52-week high of $69.85.

Peers on Argus

CG gained 5.21%, outpacing peers TPG (2.91%), TROW (2.14%), NTRS (3.39%), OWL (3.46%), and RJF (2.40%), suggesting a more company-specific boost alongside a strong group tape.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 04	Product/platform news	Positive	+1.6%	Willow Wealth added three evergreen private markets funds on its platform.
Nov 12	Acquisition	Positive	+2.2%	ARMADA bought Poseidon Industrial to expand U.S. Navy modernization services.
Oct 21	Management hires	Positive	-0.3%	Thoma Bravo Credit added two senior partners to grow private credit.
Oct 17	Equity investment	Positive	+0.3%	26North led a <b>$700M</b> equity investment in NEP to fund growth.
Oct 17	Funding/refinance	Positive	+0.3%	NEP detailed the <b>$700M</b> investment and a comprehensive debt refinancing.

Pattern Detected

Recent corporate and portfolio news, including acquisitions and capital events, most often saw modestly positive next-day moves, with one instance of divergence on otherwise constructive news.

Recent Company History

Over the last six months, CG-linked news has focused on platform expansion and portfolio transactions. Highlights include Willow Wealth offering access to evergreen funds with $11.7 billion in AUM, ARMADA’s Navy-focused acquisition on Nov 12, 2025, and NEP Group’s $700 million equity investment and debt refinancing on Oct 17, 2025. The current Resonetics acquisition continues this theme of adding specialized capabilities, aligning with prior strategic growth announcements that generally coincided with small positive price reactions.

Market Pulse Summary

This announcement highlights Resonetics’ acquisition of Med-Ally’s pulse generator manufacturing assets and IP, deepening its presence in neuromodulation, BCI, and cardiac rhythm management markets. It follows other capability-building deals within the CG ecosystem, such as prior MedTech and technology acquisitions. Investors may focus on how effectively these assets are transferred into existing facilities, the pace of customer adoption for integrated battery–generator solutions, and whether future transactions continue this niche, technology-focused expansion strategy.

Key Terms

neuromodulation medical

"a medical technology design and development company focused on the neuromodulation market"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

brain-computer-interface (BCI) medical

"serving the expanding neuromodulation, brain-computer-interface (BCI), and cardiac rhythm"

A brain-computer interface (BCI) is a technology that translates brain activity into commands a computer or device can understand, or delivers signals back to the nervous system; think of it as a translator between thoughts and machines. Investors care because BCIs could create entirely new product and service markets—medical devices, communication tools and consumer electronics—while also carrying significant technical, regulatory and ethical risks that affect potential returns.

cardiac rhythm management (CRM) medical

"brain-computer-interface (BCI), and cardiac rhythm management (CRM) markets"

Cardiac rhythm management (CRM) covers medical devices and systems that detect and correct abnormal heartbeats, such as pacemakers, defibrillators and implantable monitors. Think of CRM as a heart’s thermostat and alarm system: it keeps rhythm stable and intervenes if a dangerous pattern appears. Investors watch CRM because sales, long-term follow-up services, regulatory approvals, reimbursement rules and safety outcomes directly affect company revenue and valuation.

implantable pulse generators (IPG) medical

"implantable and external pulse generators (IPG/EPG) and leads manufacturing"

An implantable pulse generator (IPG) is a small, battery-powered medical device placed under the skin that sends electrical pulses to nerves or heart tissue to manage conditions like chronic pain or arrhythmias; think of it as a tiny, programmable remote control implanted in the body. Investors care because IPGs drive device sales, recurring revenue from follow-up care and replacements, and their market value hinges on safety, battery life, regulatory approvals, and insurance reimbursement.

external pulse generators (EPG) medical

"implantable and external pulse generators (IPG/EPG) and leads manufacturing"

An external pulse generator (EPG) is a medical device that delivers controlled electrical pulses to nerves or tissues either through the skin or via connections to an implanted system; it acts like a portable “remote control” or power source for temporary therapy, testing, or to program implantable stimulators. Investors track EPGs because they influence device adoption, clinical trial progress, regulatory clearance, recurring consumable sales and service revenue, and the overall commercial potential of neuromodulation and similar therapy markets.

intellectual property technical

"acquired the manufacturing assets, process know-how, and intellectual property related to"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

AI-generated analysis. Not financial advice.

NASHUA, N.H., Jan. 6, 2026 /PRNewswire/ -- Resonetics® announced today that it has acquired the manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators (IPG/EPG) and leads manufacturing and assembly from Med-Ally, a medical technology design and development company focused on the neuromodulation market and based in Charleston, South Carolina.

The acquisition strengthens Resonetics' Medical Power business by combining its comprehensive implantable battery technologies with advanced pulse generator manufacturing processes. This integration enables Resonetics to offer customers another critical solution, from energy source to active implantable device, serving the expanding neuromodulation, brain-computer-interface (BCI), and cardiac rhythm management (CRM) markets. As part of the deal, the acquired assets will ultimately be transferred to an existing Resonetics facility.

"This acquisition represents an important step forward for our Bioelectronic market segment," said Kevin Kelly, CEO of Resonetics. "We already provide implantable batteries that power neurostimulation and cardiac devices. Now we can manufacture the pulse generators themselves, giving customers a more integrated and efficient solution."

"Combining IPG manufacturing & assembly with Resonetics' implantable battery expertise creates a differentiated capability in the industry," added Fred Borne, VP of Fiber Optic Sensors & Medical Power at Resonetics. "We're now positioned to be the comprehensive partner for next-generation neuromodulation devices, something our customers have been seeking."

The acquisition marks the third notable transaction for Resonetics in the last twelve months, having added nitinol gun-drilling and insert- and micro-molding with the prior acquisitions of select assets from Medical Component Specialists and Eden Holdings.  The company will continue to target niche manufacturing technologies that support its focus on the most innovative market segments within the medical device industry. 

About Resonetics
Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs® and AGILE Product Development® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 18 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in over 280 companies, and the firm currently manages $45 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

View original content to download multimedia:https://www.prnewswire.com/news-releases/resonetics-expands-bioelectronics-implant-offering-with-acquisition-of-manufacturing-assets-and-process-ip-from-med-ally-302653361.html

SOURCE Resonetics, LLC

FAQ

What did Resonetics (CG) acquire from Med-Ally on January 6, 2026?

Resonetics acquired manufacturing assets, process know-how, and intellectual property for IPG/EPG and leads manufacturing and assembly.

How does the Med-Ally asset acquisition affect Resonetics' product offering (CG)?

It combines implantable battery technologies with pulse-generator manufacturing to offer end-to-end solutions from energy source to active implantable device.

Which markets will Resonetics (CG) address with the new Med-Ally capabilities?

The acquisition targets the neuromodulation, brain-computer-interface (BCI), and cardiac rhythm management (CRM) markets.

Will the acquired Med-Ally assets be integrated into Resonetics facilities (CG)?

Yes, the acquired assets will ultimately be transferred to an existing Resonetics facility.

Is this acquisition part of a broader M&A strategy for Resonetics (CG)?

Yes, this is the third notable transaction in 12 months, following acquisitions adding nitinol gun-drilling and micro-molding capabilities.